Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM ET Company Participants Scott Smith - CEO Theodora Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Why don't we get started?

Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

PITTSBURGH , June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets. Chief Executive Officer  Scott A.

Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024

Viatris Inc. (NASDAQ:VTRS ) Jefferies 2024 Global Healthcare Conference Call June 6, 2024 8:00 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Well, good morning, everybody.

Viatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript)

PITTSBURGH , June 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, June 11, 2024. Chief Executive Officer Scott A Smith and Company executives will represent the company in a fireside chat scheduled at 9:20 a.m.

Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

PITTSBURGH , June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors.

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

PITTSBURGH , May 31, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference at the Marriott Marquis Hotel in New York, NY on Thursday, June 6, 2024. Chief Executive Officer Scott A.

Viatris to Participate in the Jeffries Global Healthcare Conference

Viatris Inc. reported Q1 2024 results in line with expectations, with a 2% decline in net sales. The company's EBITDA and free cash flow have been negatively impacted by declining sales, and its debt to EBITDA ratio remains high. Despite the low P/E ratio, Viatris stock has not delivered significant returns. We go into the reasons why.

Viatris: Skeptics Proven Right Once Again

Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impact PITTSBURGH , May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building Sustainable Access at Scale. The report highlights its actions and initiatives across multiple areas of focus in support of the Company's efforts to continue to be a model for sustainable access to medicine and to make a difference in the communities it serves.

Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024.

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Viatris Inc. (NASDAQ:VTRS ) BofA Securities 2024 Health Care Conference May 14, 2024 1:00 PM ET Company Participants Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Jason Gerber - BoA Securities Jason Gerber All right, everybody, we're going to get going here with our next company presenter at the Bank Of America Annual Healthcare Conference. We got Viatris.

Viatris Inc. (VTRS) BofA Securities 2024 Health Care Conference (Transcript)

Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Viatris Inc. (NASDAQ:VTRS ) Q1 2024 Earnings Call Transcript May 9, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Conference Call Participants Nathan Rich - Goldman Sachs Bhavin Patel - Bank of America Glen Santangelo - Jefferies Ash Verma - UBS Chris Schott - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning and welcome to Viatris Q1 2024 Earnings Conference Call. All participants will be in listen-only mode.

Viatris Inc. (VTRS) Q1 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.

Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates

Drugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure.

Viagra maker Viatris misses revenue estimates on weak demand for older drugs

PITTSBURGH , May 9, 2024 /PRNewswire/ --  Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter  Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1]  Reaffirms 2024 New Product Revenue Range of $450 Million to $550 Million   Closes Idorsia Transaction, Expanding Portfolio of Innovative Assets  Closes Women's Healthcare Business Divestiture  Reaffirms 2024 Financial Guidance After Adjusting the Ranges Solely to Reflect the Impact of Divestitures and Acquired IPR&D[2]  Returns $393 Million of Capital to Shareholders in First Quarter Through Dividends and Share Repurchases  Board of Directors Declares Quarterly Dividend of $0.12 per Share Viatris Inc. (NASDAQ: VTRS) today announced its financial results for the first quarter of 2024, which reflect continued momentum and the strength of its base business. Executive Commentary Viatris CEO Scott A.

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges

Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Viatris (VTRS)

ACADIA Pharma

Iovance Biotherapeutics

Perrigo

Teva Pharmaceutical

Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

Evaluate the expected performance of Viatris (VTRS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

PITTSBURGH , May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024. Chief Financial Officer Doretta Mistras  and Chief R&D Officer Philippe Martin  will represent the company in a fireside chat scheduled at 10 a.m.

Viatris to Participate in the BofA Securities 2024 Health Care Conference

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

PITTSBURGH and LONDON , May 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, recently launched Unmind as part of its global wellbeing program, Elevate. Unmind is a leading provider of workplace mental health solutions designed by psychologists to help individuals understand and be proactive with their mental health and lead healthier, happier lives.

Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health

The Inflation Reduction Act has reduced the exclusivity period for small-molecule drugs, potentially leading to earlier market entry for generic drugs. The shortened exclusivity period may create a bullish catalyst for certain stocks in the generic pharmaceutical sector. Gilead will face a patent "mini-cliff" in the near future, providing opportunities for generic drug manufacturers.

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Dr. Reddy's Labs

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.

News for Viatris Stock (VTRS)